论文信息 - A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. - 字舞流文

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Joon-Oh Park | A. Varghese | D. Melisi | J. Bendell | S. Estrem | S. Faivre | R. García-Carbonero | M. Man | D. Oh | A. Hollebecque | E. Calvo | E. Borazanci | I. Gueorguieva | K. Benhadji | S. Guba | F. Simionato | Yumin Zhao | M. Lanasa | T. M. Mercadé